Login to Your Account

Chelsea Dealt Another Potential Blow on NOH Drug Northera

By Marie Powers
Staff Writer

Tuesday, February 14, 2012
Chelsea Therapeutics International Inc. delivered unhappy news Monday morning, acknowledging the FDA had raised questions about safety and efficacy in a briefing document released in advance of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting on the new drug application (NDA) for lead candidate Northera (droxidopa), scheduled for Feb. 23.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription